COMIRNATY

This brand name is authorized in Austria, Canada, Estonia, Spain, Finland, France, Croatia, Ireland, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Tunisia, United Kingdom, United States, South Africa

Active ingredients

The drug COMIRNATY contains one active pharmaceutical ingredient (API):

1 Tozinameran
UNII 5085ZFP6SJ - TOZINAMERAN

The nucleoside-modified messenger RNA in COVID-19 mRNA Vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19 disease.

Read about Tozinameran

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
COVID-19 mRNA VACCINE BNT162b2 Concentrate for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
COMIRNATY Concentrate for dispersion for injection European Medicines Agency (EU) MPI, EU: SmPC
PFIZER-BIONTECH COVID-19 VACCINE BNT162b2 Suspension for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J07BN01 J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines
Discover more medicines within J07BN01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02509210
Country: EE Ravimiamet Identifier(s): 1834422, 1864481, 1864492, 1865280, 1865291, 1887947, 1887958, 1888106, 1888117
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 1201528001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 165049, 488024, 516605
Country: FR Base de données publique des médicaments Identifier(s): 60495328
Country: JP 医薬品医療機器総合機構 Identifier(s): 631341DA1025, 631341DA2021, 631341DA4024, 631341JA1021, 631341JA2028, 631341JA3024
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1091557
Country: NL Z-Index G-Standaard, PRK Identifier(s): 206784
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 21938, 22857, 22858
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100444490, 100461238, 100462404
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W67224002, W68305001, W68305002, W68306001, W68306002, W69194001, W69194002, W69195001, W69195002, W69238001, W69311001, W69311002
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 24893012EP
Country: US FDA, National Drug Code Identifier(s): 59267-1000
Country: ZA Health Products Regulatory Authority Identifier(s): 56/30.2/0002

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.